Advanced driver gene-negative non-small cell lung cancer is generally considered incurable, and treatment aims to prolong patient survival. Recently, however, a new definition “oligometastasis” has been proposed, which refers to the appearance of no more than 5 metastatic lesions in up to 3 different organs. The emergence of this concept has changed the traditional treatment model. Many studies have shown that standard systemic therapy combined with local therapy (radiotherapy, surgery, thermal ablation, etc.) can effectively prolong the survival time of these patients. This article reviews the clinical studies on the efficacy, toxicity, and beneficiary population of local radiotherapy combined with systemic therapy in driver gene-negative oligometastatic non-small cell lung cancer, and provides further reference for clinical decision-making.
